These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1378231)

  • 1. Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment.
    Hegbrant J; Thysell H; Ekman R
    Scand J Urol Nephrol; 1992; 26(2):169-76. PubMed ID: 1378231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in plasma levels of vasoactive peptides during standard bicarbonate hemodialysis.
    Hegbrant J; Thysell H; Mårtensson L; Ekman R; Boberg U
    Nephron; 1993; 63(3):303-8. PubMed ID: 8446268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of gastrointestinal regulatory peptides in patients receiving maintenance hemodialysis.
    Hegbrant J; Thysell H; Ekman R
    Scand J Gastroenterol; 1991 Jun; 26(6):599-604. PubMed ID: 1713707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in plasma levels of vasoactive peptides during sequential bicarbonate hemodialysis.
    Hegbrant J; Thysell H; Mårtensson L; Ekman R; Boberg U
    Nephron; 1993; 63(3):309-13. PubMed ID: 8446269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin and vasoactive peptides in hemodialysis patients.
    Hegbrant J; Ekman R; Thysell H
    Blood Purif; 1998; 16(3):135-9. PubMed ID: 9681155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of recombinant human erythropoietin on the plasma levels of vasoactive regulatory peptides in patients on maintenance hemodialysis.
    Hegbrant J; Thysell H; Ekman R
    Int J Artif Organs; 1991 Jul; 14(7):411-6. PubMed ID: 1889894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sham hemodialysis on plasma levels of vasoactive peptides in patients with uremia.
    Hegbrant J; Mårtensson L; Thysell H; Ekman R; Boberg U
    ASAIO J; 1992; 38(3):M197-200. PubMed ID: 1281014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dialysis fluid temperature and vasoactive substances during routine hemodialysis.
    Hegbrant J; Mãrtensson L; Ekman R; Nielsen AL; Thysell H
    ASAIO J; 1994; 40(3):M678-82. PubMed ID: 8555600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin treatment and plasma levels of corticotropin-releasing hormone, delta sleep-inducing peptide and opioid peptides in hemodialysis patients.
    Hegbrant J; Thysell H; Ekman R
    Scand J Urol Nephrol; 1992; 26(4):393-6. PubMed ID: 1337953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated plasma levels of opioid peptides and delta sleep-inducing peptide but not of corticotropin-releasing hormone in patients receiving chronic hemodialysis.
    Hegbrant J; Thysell H; Ekman R
    Blood Purif; 1991; 9(4):188-94. PubMed ID: 1667974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of atrial natriuretic peptide, arginine vasopressin and hormones of the renin-angiotensin system in patients with end-stage renal disease.
    Elias AN; Vaziri ND; Pandian MR; Kaupke J
    Int J Artif Organs; 1989 Mar; 12(3):153-8. PubMed ID: 2526100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma vasopressin, catecholamines and atrial natriuretic factor during hemodialysis and sequential ultrafiltration.
    Os I; Nordby G; Lyngdal PT; Eide I
    Scand J Urol Nephrol; 1993; 27(1):93-9. PubMed ID: 8493477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma levels of vasoactive substances during routine acetate and bicarbonate hemodialysis.
    Hegbrant J; Mårtensson L; Thysell H; Ekman R; Boberg U
    Clin Nephrol; 1994 Feb; 41(2):106-12. PubMed ID: 8004826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptide-Y and atrial natriuretic peptide as prognostic markers in patients on hemodialysis.
    Odar-Cederlöf I; Ericsson F; Theodorsson E; Kjellstrand CM
    ASAIO J; 2003; 49(1):74-80. PubMed ID: 12558311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma neuropeptide levels in psoriasis.
    Mozzanica N; Cattaneo A; Vignati G; Finzi A
    Acta Derm Venereol Suppl (Stockh); 1994; 186():67-8. PubMed ID: 7521105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropeptide variability in man.
    Onuoha GN; Nugent AM; Hunter SJ; Alpar EK; McEneaney DJ; Campbell NP; Shaw C; Buchanan KD; Nicholls DP
    Eur J Clin Invest; 2000 Jul; 30(7):570-7. PubMed ID: 10886296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma neuropeptides in hyperthyroidism.
    Erfurth EM; Ekman R; Ahrén B
    Thyroidology; 1990 Aug; 2(2):59-63. PubMed ID: 1724911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated neuropeptide levels decrease during liver transplant.
    D'Souza M; Plevak D; Kvols L; Shine T; Stapelfeldt W; Nelson D; Southorn P; Murray M
    Transplant Proc; 1993 Apr; 25(2):1805-6. PubMed ID: 7682353
    [No Abstract]   [Full Text] [Related]  

  • 19. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo.
    Mozzanica N; Villa ML; Foppa S; Vignati G; Cattaneo A; Diotti R; Finzi AF
    J Am Acad Dermatol; 1992 May; 26(5 Pt 1):693-700. PubMed ID: 1316387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.